Enliven Therapeutics Inc. (ELVN)
22.67
2.21 (10.80%)
At close: Jan 15, 2025, 1:23 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Net Income | -71.58M | -37.66M | -24.74M | -18.97M | -23.46M | -11.34M | n/a |
| Depreciation & Amortization | 297.00K | 215.00K | 115.00K | 45.00K | 33.00K | n/a | n/a |
| Stock-Based Compensation | 12.91M | 3.19M | 1.92M | 130.00K | 899.00K | 555.00K | n/a |
| Other Working Capital | 3.65M | 27.00K | 1.83M | 292.00K | -77.00K | 758.00K | 478.00K |
| Other Non-Cash Items | -4.30M | 1.74M | 3.81M | 9.68M | 196.00K | 848.00K | -7.93M |
| Deferred Income Tax | n/a | n/a | -3.81M | n/a | -215.00K | n/a | n/a |
| Change in Working Capital | 1.40M | 438.00K | 3.57M | 583.00K | 673.00K | 1.24M | -188.00K |
| Operating Cash Flow | -61.27M | -32.08M | -19.13M | -8.53M | -21.88M | -8.78M | -8.79M |
| Capital Expenditures | -149.00K | -612.00K | -191.00K | -461.00K | -140.00K | n/a | n/a |
| Acquisitions | n/a | 35.00M | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | -268.26M | -35.00M | -47.56M | -64.20M | -23.92M | n/a | n/a |
| Sales Maturities Of Investments | 120.00M | 41.88M | 45.94M | 47.50M | n/a | n/a | n/a |
| Other Investing Acitivies | n/a | -41.88M | 1.62M | 16.70M | n/a | n/a | n/a |
| Investing Cash Flow | -148.41M | -612.00K | -191.00K | -461.00K | -24.06M | n/a | n/a |
| Debt Repayment | n/a | n/a | n/a | n/a | -2.00M | n/a | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 234.29M | -1.80M | -1.24M | 260.89M | n/a | 6.49M | 11.00M |
| Financial Cash Flow | 234.29M | -1.80M | -1.02M | 130.51M | 43.58M | 6.49M | 11.00M |
| Net Cash Flow | 24.61M | -34.49M | -20.34M | 121.52M | -2.45M | -2.29M | 2.21M |
| Free Cash Flow | -61.42M | -32.69M | -19.32M | -8.99M | -22.02M | -8.78M | -8.79M |